Skip to main content

News

Methotrexate significantly lowers Systolic BP

Australian researchers have shown that methotrexate (MTX) has another secondary, beneficial effect by significantly lowering systolic blood pressure, and contributes to its well docuented cardioprotive effecs.

ACR Concerns on the Scientific Integrity at the CDC

ACR

On behalf of the American College of Rheumatology (ACR), we express deep concern over recent developments at the Centers for Disease Control and Prevention (CDC) that appear to undermine the agency’s longstanding commitment to science-based public health policy.

Crepitus Does Not Predict Earlier/Worse OA

EurekAlert!

Young adults who experience grinding or clicking sounds in their knees post-surgery may be alarmed, but new research from La Trobe University suggests these sounds may not signal early-onset osteoarthritis. 

Multi-omics, biomarkers, rheumatoid arthritis and pulmonary fibrosis

Rheumatoid arthritis (RA) is a common autoimmune disease, and approximately 30%-40% of patients develop pulmonary complications such as idiopathic pulmonary fibrosis (IPF), but the causal relationship between the two has long been unclear.

Higher Medical Costs with Corticosteroid Use

Rheumatoid arthritis (RA) health insurance claims database study from Japan shows that RA patients initially treated with glucocorticoids (GCs) and disease-modifying antirheumatic drugs (DMARDs) experienced greater medical costs and healthcare utilization than patients not trea

Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease

Rheumatoid arthritis interstitial lung disease (RA-ILD) represents a major therapeutic evidence void in our current treatment paradigm. RA-ILD is common, with clinically significant disease seen in 8% of patients. In the past RA-ILD was frequently under-diagnosed, leading to identification of a disproportionate volume of severe cases and subsequently inflating the mortality statistics. However, RA-ILD, particularly in the progressive pulmonary fibrosis phenotype, retains a poor prognosis. I would propose a new framework for RA-ILD treatment.

ILD Begins (8.29.2025)

Dr. Jack Cush reviews the news and journal reports from RheumNow.com. This week news on vaccines, safety of acetaminophen and more.

ACR Urges Alaska and Montana to Strengthen Rheumatology Care

ACR

The American College of Rheumatology (ACR) is calling on Alaska and Montana to seize the opportunity to address critical gaps in rheumatology care by accessing funding from the Rural Health Transformation Program (RHTP), provided by the One Big Beautiful Bill Act (H.R.

Long-term Lab Monitoring in RA is Inefficient

Annals of Internal Medicine has published a retrospective study of long-term routine laboratory toxicity monitoring (lt-RLTM) in patients receiving disease-modifying antirheumatic drug (DMARD) therapy showing that most very abnormal laboratory finding occur early in therapy (first 6 months) or are anticipated or only after dose escalation.

Osteoporosis in Older Men

JAMA has publish an invited commentary on Screening for Osteoporosis (OP) in Older Men. They point out that a simple screening strategy for older men based on previous fracture history and bone density screening at age 70 or 75 years is a reasonable means of screening for OP in older men.

Ambient Dictation Works and Reduces Burnout

MedPage Today
Passive documentation of clinic visits using artificial intelligence (AI)-drafted notes was linked to reduced burnout and improved well-being, a survey study from two academic medical centers suggested.

Methotrexate intolerance in rheumatoid arthritis

Methotrexate (MTX) is the most commonly used DMARD in rheumatoid arthritis (RA); however, there is significant intolerance to this drug among adult RA patients - especially at doses above 15 mg per week. 

×